on Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained development and commercialization rights to giroctocogen fitelparvovec, an investigational gene therapy product candidate in moderate to severe hemophilia A that it has co-developed and licensed to Pfizer Inc (NYSE:PFE).

Pfizer decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all options for moving the program forward, including seeking a potential new collaboration partner.

Read also: FDA approves Pfizer’s second hemophilia drug in six months

In July 2024, Pfizer announced the primary results of the phase 3 AFFINE trial of giroctocogen fitelparvovec, which showed that the trial met the primary and key secondary objectives of superiority. compared to prophylaxis.

“…we believe it is well positioned for regulatory filings and potential commercialization,” said Sandy Macrae, CEO of Sangamo Therapeutics. “While we were surprised and extremely disappointed by Pfizer’s decision to end our collaboration so close to the advance BLA and MAA submissions…”

The collaboration and license agreement with Pfizer will end on April 21, 2025. All trial participants will continue to be monitored as planned during the transition period.

Sangamo believes that its recently announced partnerships with Roche Holdings AG (OTC:RHHBY) Genentech i Astellas Pharma Inc (OTC:ALPMF) (OTC:ALPMIA) and advanced business development discussions for its Fabry gene therapy program will allow it to chart a path forward for its neurological genomic medicine pipeline.

The company is preparing to initiate the planned enrollment of patients in the Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and submit a clinical trial authorization submission planned for the prion disease program by 4th 2025, each subject to securing additional funding.

Price action: Shares of SGMO traded down 54.70% to $1.106 during the pre-market session of last check on Tuesday.

Read Next:

Next: Transform your business with Benzinga Edge’s unique market trading ideas and tools. Click now to access unique insights that can get ahead of you in today’s competitive market.

Get the latest Benzinga stock analysis?

This article Sangamo Therapeutics shares fall as Pfizer ends hemophilia gene therapy deal originally appeared Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.